Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Appl Microbiol Biotechnol 105 , 91039111 (2021)
As more research is conducted, particularly in human trials, our understanding of its efficacy will continue to grow
NNMT uses up nicotinamide by tagging it with a methyl group (a process called methylation) and sending it out as waste
AOD 9604 works by stimulating the release of fatty tissue while preventing fatty tissue growth
the underlying research base is scientifically legitimate